CD4 and COVID-19: In addition, a rapid and significant CD4+ and CD8+ T lymphopenia was associated with adverse disease outcome during SARS-CoV (9, 11) and MERS-CoV infection (12), as it has been widely reported during the severe course of COVID-19 (13, 14).